🇺🇸 FDA

Intelligence · Clinical Pipeline

HOFFMANN-LA ROCHE Pipeline

All ClinicalTrials.gov programs at HOFFMANN-LA ROCHE — phase, modality, and trial IDs.

Programs
58

Quick answer

HOFFMANN-LA ROCHE has 58 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. A Phase I Study of RO7589831 in Participants with Advanced Solid Tumors

    Hoffmann-La Roche

    Advanced solid tumors

    phase 1 other active

    1 trial

  2. A SINGLE-CENTER, OPEN-LABEL, TWO-PERIOD STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE ITRACONAZOLE, A STRONG CYP3A INHIBITOR, ON THE PHARMACOKINETICS OF A SINGLE 30 MG DOSE OF RO7269162 IN HEALTHY PARTICIPANTS

    Hoffmann-La Roche

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  3. A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC)

    Hoffmann-La Roche

    Metastatic Colorectal Cancer

    phase 1 other active

    1 trial

  4. A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma

    Hoffmann-La Roche

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  5. A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

    Hoffmann-La Roche

    Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular lymphoma, High grade B-cell lymphoma (HGBL), Epstein-Barr virus−positive DLBCL

    phase 1 other active

    1 trial

  6. A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patients with Alzheimer’s Disease

    Hoffmann-La Roche

    Alzheimer’s Disease (AD)

    phase 1 other active

    1 trial

  7. A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD)

    Hoffmann-La Roche

    Huntington’s Disease Gene Expansion Carriers

    phase 1 other active

    1 trial

  8. A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination with Atezolizumab in Participants with Advanced and/or Metastatic Solid Tumors

    Hoffmann-La Roche

    Solid Tumors

    phase 1 other active

    1 trial

  9. A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe Asthma

    Hoffmann-La Roche

    Moderate to Severe Asthma

    phase 1 other active

    1 trial

  10. A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Participants with BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with Central Nervous System Metastases

    Hoffmann-La Roche

    BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with or without Central Nervous System Metastases

    phase 1 other active

    1 trial

  11. A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants with Type 2 Diabetes Mellitus(T2DM) and Overweight or Obesity

    Hoffmann-La Roche

    Type 2 Diabetes Mellitus (T2DM) and overweight or obesity

    phase 1 other active

    1 trial

  12. A Study to Evaluate the Effects of Various Degrees of Hepatic Impairment on the Pharmacokinetics of A Single Subcutaneous Dose Of RO7434656, an Antisense Inhibitor of Complement Factor B

    Hoffmann-La Roche

    Hepatic Impairment

    phase 1 other active

    1 trial

  13. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    Hoffmann-La Roche

    Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  14. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination with Glofitamab in Participants with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

    Hoffmann-La Roche

    Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r NHL)

    phase 1 other active

    1 trial

  15. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants with Systemic Lupus Erythematosus

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 1 other active

    1 trial

  16. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Inavolisib in Combination with Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors

    Hoffmann-La Roche

    Locally Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  17. A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How The Body Notices and Reacts To It, And Its Effect On The Body When Given As A Subcutaneous Injection In Patients With Multiple Sclerosis

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  18. A Study to Investigate the Effect of RO7504109 on Immune Cells in Healthy Participants

    Hoffmann-La Roche

    Not Applicable (N/A)

    phase 1 other active

    1 trial

  19. A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  20. A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous and Subcutaneous Administration in Participants with Multiple Sclerosis

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  21. A Study to Test How Safe, Effective and How Body’s Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

    Hoffmann-La Roche

    Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL)

    phase 1 other active

    1 trial

  22. A Study to Track How the Healthy Male Participants Handles the New Oral Drug RO7795081 for Weight Management and Diabetes

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  23. A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants with Advanced Solid Tumors

    Hoffmann-La Roche

    Advanced Solid Tumors Harboring RAS Mutation(S)

    phase 1 other active

    1 trial

  24. A Study to find out the safety, tolerability and interaction of drug with body (including the effect of Itraconazole on RO7268489) and also what the body does to RO7268489 after oral intake by healthy participants

    Hoffmann-La Roche

    Not applicable

    phase 1 other active

    1 trial

  25. A Study to see how safe is RO7567132 as Single Agent and in Combination with Atezolizumab, how the body gets rid of it and how effective it is in people with Advanced and/or Metastatic Solid Tumors

    Hoffmann-La Roche

    Advanced and/or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  26. A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs are at different doses.

    Hoffmann-La Roche

    HER2-positive advanced solid tumours

    phase 1 other active

    1 trial

  27. A study comparing different RO7269162 capsules and investigating the effect of food on the uptake, breakdown, and elimination of RO7269162 in Healthy Participants

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  28. A study investigating the effect of different approved medications on how the body processes the study compound RO7795081. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control.

    Hoffmann-La Roche

    Type 2 Diabetes and obesity

    phase 1 other active

    1 trial

  29. A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Hoffmann-La Roche

    Obesity or Overweight

    phase 1 other active

    1 trial

  30. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  31. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Healthy volunteers

    phase 1 other active

    1 trial

  32. A study investigating the safety, absorption, and elimination of RO7795081, a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  33. A study investigating the safety, absorption, and elimination of radioactively labeled RO7269162, a new compound that may potentially be used in the treatment of Alzheimer’s disease.

    Hoffmann-La Roche

    Healthy males volunteers

    phase 1 other active

    1 trial

  34. A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 in participants with Advanced Small Cell Lung Cancer and other Neuroendocrine Carcinomas

    Hoffmann-La Roche

    Small Cell Lung Cancer and Neuroendocrine Carcinoma

    phase 1 other active

    1 trial

  35. A study to see how RO7763505 works and how safe it is when given to healthy people and people with stable heart disease

    Hoffmann-La Roche

    Stable Coronary Artery Disease (CAD)

    phase 1 other active

    1 trial

  36. A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.

    Hoffmann-La Roche

    Parkinson’s Disease

    phase 1 other active

    1 trial

  37. An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis

    Hoffmann-La Roche

    Active Ulcerative Colitis (UC)

    phase 1 other active

    1 trial

  38. An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.

    Hoffmann-La Roche

    Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  39. Atezolizumab

    Hoffmann-La Roche

    Advanced Ovarian Cancer

    phase 1 small molecule terminated

    1 trial

  40. First-in-Human Study of RO7812653

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)

    phase 1 other active

    1 trial

  41. Ipatasertib

    Hoffmann-La Roche

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  42. Midazolam

    Hoffmann-La Roche

    Hepatitis B, Chronic

    phase 1 small molecule completed

    1 trial

  43. Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives

    Hoffmann-La Roche

    Healthy Overweight or Obese

    phase 1 other active

    1 trial

  44. Onartuzumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  45. PEG-IFN alfa-2a BA-free formulation (Test)

    Hoffmann-La Roche

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  46. Placebo - MAD

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  47. RO5323441

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  48. RO5503781

    Hoffmann-La Roche

    Neoplasms

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does HOFFMANN-LA ROCHE have?

58 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.